Girgis, RR, Phillips, MR, Li, X, Li, K, Jiang, H, Wu, C, et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year randomised clinical trial. Br J Psychiatry
2011; 199: 281–8.
Spielmans, GI, Parry, PI. From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. Bioethic Inq
2010; 7: 13–29.
Kissling, W, Davis, JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict. Psychol Med
2009; 39: 1591–602.
National Collaborating Centre for Mental Health. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care
. British Psychological Society and Royal College of Psychiatrists, 2010.
Elkes, J, Elkes, C. Effect of chlorpromazine on the behaviour of chronically overactive psychotic patients. BMJ
1954; 2: 560–5.
Kerwin, RW. Clozapine: back to the future for schizophrenia research. Lancet
1995; 345: 1063–4.
Hippius, H. The history of clozapine. Psychopharmacology
1989; 99: S3–5.
Healy, D. The Creation of Psychopharmacology. Harvard University Press, 2002.
Janssen, PA, Niemegeers, CJ, Awouters, F, Schellekens, KH, Megens, AA, Meert, TF. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine D2 antagonistic properties. J Pharmacol Exp Ther
1988; 244: 685–93.
National Institute for Clinical Excellence. Guidance on Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. . NICE, 2002.
Geddes, J, Freemantle, N, Harrison, P, Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ
2000; 321: 1371–6.
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
Jones, PB, Barnes, TRE, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry
2006; 63: 1079–87.
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet
2009; 373: 31–41.
Whittington, CJ, Kendall, T, Fonagy, P, Cottrell, D, Cotgrove, A, Boddington, E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet
2004; 363: 1341–5.
Turner, EH, Matthews, AM, Linardatos, E, Tell, RA, Rosenthal, R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med
2008; 358: 252–60.